{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
RCC Survey
  1. How many patients of RCC do you see every year? *

  2. From your clinical experience, mention the stage wise % of RCC patients that present to you at diagnosis? *
    3. Stage-I
    %
    Stage-II
    %
    Stage-III
    %
    Stage-IV
    %
  3. Among all the metastatic RCC patients you see every year, what % of patients are *
    4. De-novo metastatic patients
    %
    Progressed from early stage to advanced stage
    %
  4. From your clinical experience, What % of your metastatic RCC patients belong to these IMDC risk groups *
    5. Favourable
    %
    Intermediate
    %
    Poor
    %

    %
  5. From your clinical experience, What % of your metastatic RCC patients received prior adjuvant therapy in early stage. *

  6. What is the average duration of treatment for the below molecules in 1st line and 2nd line mRCC? *
    7. Sunitinib
    Pazopanib
  7. While using Sunitinib as a 1st line Tx for advanced RCC, which schedule do you prefer *
    8. 4 weeks on 2 weeks off
    2 weeks on 1 week off
  8. If you prefer sunitinib 2 weeks on 1 week off schedule as 1st Line for mRCC patients, please state your reasons (please tick one or more)

  9. What share of your newly diagnosed advanced RCC on *
    10. Sorafenib
    %
    Sunitinib
    %
    Pazopanib
    %
    Cabozantinb
    %
    Immunotherapy
    %
    {{--
  10. In COMPARZ trial (Sunitinib vs Pazopanib), Pazopanib had shown more treatment discontinuation. *

    11. Do you observe the same in your clinical practice?

    --}}
  11. In which set of mRCC patients do you prefer Sunitinib over Pazopanib? *
    12. a
    b
    c
    d
  12. In which set of mRCC patients do you prefer Pazopanib over Sunitinib? *
    13. a
    b
    c
    d
  13. In your clinical practice, on an average how many cycles of pazopanib do most mRCC patients takes (In first line setting)? *

  14. In your clinical practice, on an average how many cycles of Sunitinib (4/2 week schedule) do most mRCC patients takes (In first line setting)? *

  15. In your clinical practice, on an average how many cycles of Sunitinib (2/1 week schedule) do most mRCC patients takes (In first line setting)? *

  16. Which is your preferred TKI for mRCC patients with prior history of nephrectomy *

  17. For clear cell mRCC patients, which Immunotherapy based regimen do you prefer in your clinical practice *
    18. IMDC Favourable risk IMDC Intermediate/poor risk

  18. For the management of relapsed mRCC, do you feel Cabozantinib is superior over other available TKIs. *

  19. In your clinical practice, what is your preferred treatment sequence for mRCC in 1st line and 2st line setting (Unaffordable to Immunotherapy)? *

  20. A. Where do you see the scope of Lenvatinib Plus Everolimus in advanced RCC? *
    B. Have you used this combination in the setting mentioned above?
    21. {{--
    --}}
  21. For non-clear cell mRCC, which will be your preferred TKI of choice? *